Xenon Pharmaceuticals (XENE) Expected to Announce Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to be posting its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of ($1.13) per share and revenue of $1.33 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the prior year, the company earned ($1.07) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post ($4.66) EPS for the current fiscal year and ($4.83) EPS for the next fiscal year.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $37.41 on Friday. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of -7.89 and a beta of 0.60. The firm has a 50-day simple moving average of $45.35 and a two-hundred day simple moving average of $52.21. Xenon Pharmaceuticals has a one year low of $33.38 and a one year high of $72.66.

Insiders Place Their Bets

In related news, Director Steven Gannon sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director directly owned 1,870 shares of the company’s stock, valued at $119,792.20. This represents a 84.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ian Mortimer purchased 30,000 shares of the firm’s stock in a transaction on Wednesday, September 30th. The stock was acquired at an average price of $37.38 per share, with a total value of $1,121,400.00. Following the completion of the purchase, the chief executive officer owned 49,923 shares of the company’s stock, valued at $1,866,121.74. The trade was a 150.58% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 2.91% of the company’s stock.

Wall Street Analysts Forecast Growth

XENE has been the topic of a number of analyst reports. Needham & Company LLC cut their price objective on shares of Xenon Pharmaceuticals from $78.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. Jefferies Financial Group reissued a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, September 28th. HC Wainwright reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, October 2nd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the company from $90.00 to $46.00 in a research note on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.14.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for neurological and psychiatric disorders. The company uses expertise in human genetics and ion-channel biology to identify potential treatments for diseases with significant unmet medical needs, particularly epilepsy and other disorders of the nervous system.

Xenon’s lead investigational product is azetukalner, also known as XEN1101, a selective potassium-channel opener being evaluated for epilepsy and other potential neurological and psychiatric applications.